Description: Recombinant monoclonal antibody to HepA. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from phage display HA6. This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.
Species and Isotype: Human IgG1, Fc Silent™, kappa
Clone Number: HA6
UniProt Accession Number of Target Protein:
Published Application(s): Radioimmunofocus inhibition assays; ELISA;
Published Species Reactivity: Virus (HepA)
Immunogen: Generated mAbs to HAV by phage display of the antibody library generated from the peripheral blood lymphocytes of immune donor recovered from hepatitis A. The cDNAs encoding the immunoglobulin gamma1 Fd and kappa light chains were synthesized from total RNA of the PBLs of the HAV-immune donors and cloned into a phage display vector to construct a combinatorial library of clones. The phage-displayed Fab library was panned four times against HAV. Analysis of the antigen-binding activities of the pooled phages after each round of the panning indicated that HAV-binding phage clones were almost selected after the third round of panning. Finally, 24 phage clones after the fourth panning were selected, and the gene III fragment was removed to produce soluble Fab. Analysis of the antigen-binding activities of the 24 Fab clones by ELISA revealed that 22 clones were positive in HAV binding, which could be grouped into 4 different clones; HA1, HA6, HA9, and HA12.
Specificity: Reactive to both 14S and 70S HAV particles. HA1 and HA12 recognise distinct epitopes, whereas HA6 recognises an epitope that overlaps with that of HA1 or HA12. Competitive binding assays have shown that all of these mAbs overlap with the epitopes bound by murine mAb in a single immunodominant neutralisation site on the HAV capsid. HA6 has the highest reactivity of these anti-HAV mAbs.
Application Notes: HA6 has been shown to have HAV-neutralising activity through its use in radioimmunofocus inhibition assays (Kim 2003). HA6 may be useful in the immunoprophylaxis of HAV infection.
Antibody First Published in:
Kim SJ et al. Neutralizing human monoclonal antibodies to hepatitis A virus recovered by phage display Virology. 2004 Jan 20;318(2):598-607. Note on publication: Describes the generation and characterisation of anti-HAV mAbs.

Product Form

Purification: Protein A affinity purified
Supplied in: PBS with preservative (0.02% Proclin 300)
Storage Recommendation: Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C
Concentration: See vial label.